Combination chemotherapy with carboplatin and etoposide for elderly patients aged 76 years or older with small cell lung cancer

Atsuhiko Tada, Hiroshi Ueoka, Katsuyuki Kiura, Masahiro Tabata, Mitsuhiro Takemoto, Hiromichi Yamane, Junichiro Hiyama, Keisuke Aoe, Takuo Shibayama, Haruhito Kamei, Shin Kawahara, Shingo Harita, Toshio Sato, Makoto Kobayashi, Kenji Eguchi, Shunkichi Hiraki, Yoshio Hiraki, Mitsune Tanimoto

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Eighteen elderly patients aged 76 years or older with small cell lung cancer were treated with carboplatin (AUC = 4 mg/ml.min, i.v. day 1) and etoposide (70 mg/m2 i.v. day 1-3) and 17 patients were evaluable. The median age of the study population was 77 years (range: 76-81). Eight patients had limited disease (LD) and nine did extensive disease (ED). The overall response rate was 88% for LD patients and 67% for ED patients. Median survival time was 219 days for LD patients and 158 days for ED patients. Grade 3 and 4 leukopenia, neutropenia, thrombocytopenia and anemia occurred in 41%, 76%, 24% and 6% of patients, respectively. There was one treatment-related death due to pneumonitis.

Original languageEnglish
Pages (from-to)751-756
Number of pages6
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume29
Issue number5
Publication statusPublished - May 2002

Fingerprint

Carboplatin
Small Cell Lung Carcinoma
Etoposide
Combination Drug Therapy
Leukopenia
Neutropenia
Thrombocytopenia
Area Under Curve
Anemia
Pneumonia
Survival
Population

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Combination chemotherapy with carboplatin and etoposide for elderly patients aged 76 years or older with small cell lung cancer. / Tada, Atsuhiko; Ueoka, Hiroshi; Kiura, Katsuyuki; Tabata, Masahiro; Takemoto, Mitsuhiro; Yamane, Hiromichi; Hiyama, Junichiro; Aoe, Keisuke; Shibayama, Takuo; Kamei, Haruhito; Kawahara, Shin; Harita, Shingo; Sato, Toshio; Kobayashi, Makoto; Eguchi, Kenji; Hiraki, Shunkichi; Hiraki, Yoshio; Tanimoto, Mitsune.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 29, No. 5, 05.2002, p. 751-756.

Research output: Contribution to journalArticle

Tada, A, Ueoka, H, Kiura, K, Tabata, M, Takemoto, M, Yamane, H, Hiyama, J, Aoe, K, Shibayama, T, Kamei, H, Kawahara, S, Harita, S, Sato, T, Kobayashi, M, Eguchi, K, Hiraki, S, Hiraki, Y & Tanimoto, M 2002, 'Combination chemotherapy with carboplatin and etoposide for elderly patients aged 76 years or older with small cell lung cancer', Gan to kagaku ryoho. Cancer & chemotherapy, vol. 29, no. 5, pp. 751-756.
Tada, Atsuhiko ; Ueoka, Hiroshi ; Kiura, Katsuyuki ; Tabata, Masahiro ; Takemoto, Mitsuhiro ; Yamane, Hiromichi ; Hiyama, Junichiro ; Aoe, Keisuke ; Shibayama, Takuo ; Kamei, Haruhito ; Kawahara, Shin ; Harita, Shingo ; Sato, Toshio ; Kobayashi, Makoto ; Eguchi, Kenji ; Hiraki, Shunkichi ; Hiraki, Yoshio ; Tanimoto, Mitsune. / Combination chemotherapy with carboplatin and etoposide for elderly patients aged 76 years or older with small cell lung cancer. In: Gan to kagaku ryoho. Cancer & chemotherapy. 2002 ; Vol. 29, No. 5. pp. 751-756.
@article{5bc671c5e64d4183a60ec7c42bbb280c,
title = "Combination chemotherapy with carboplatin and etoposide for elderly patients aged 76 years or older with small cell lung cancer",
abstract = "Eighteen elderly patients aged 76 years or older with small cell lung cancer were treated with carboplatin (AUC = 4 mg/ml.min, i.v. day 1) and etoposide (70 mg/m2 i.v. day 1-3) and 17 patients were evaluable. The median age of the study population was 77 years (range: 76-81). Eight patients had limited disease (LD) and nine did extensive disease (ED). The overall response rate was 88{\%} for LD patients and 67{\%} for ED patients. Median survival time was 219 days for LD patients and 158 days for ED patients. Grade 3 and 4 leukopenia, neutropenia, thrombocytopenia and anemia occurred in 41{\%}, 76{\%}, 24{\%} and 6{\%} of patients, respectively. There was one treatment-related death due to pneumonitis.",
author = "Atsuhiko Tada and Hiroshi Ueoka and Katsuyuki Kiura and Masahiro Tabata and Mitsuhiro Takemoto and Hiromichi Yamane and Junichiro Hiyama and Keisuke Aoe and Takuo Shibayama and Haruhito Kamei and Shin Kawahara and Shingo Harita and Toshio Sato and Makoto Kobayashi and Kenji Eguchi and Shunkichi Hiraki and Yoshio Hiraki and Mitsune Tanimoto",
year = "2002",
month = "5",
language = "English",
volume = "29",
pages = "751--756",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "5",

}

TY - JOUR

T1 - Combination chemotherapy with carboplatin and etoposide for elderly patients aged 76 years or older with small cell lung cancer

AU - Tada, Atsuhiko

AU - Ueoka, Hiroshi

AU - Kiura, Katsuyuki

AU - Tabata, Masahiro

AU - Takemoto, Mitsuhiro

AU - Yamane, Hiromichi

AU - Hiyama, Junichiro

AU - Aoe, Keisuke

AU - Shibayama, Takuo

AU - Kamei, Haruhito

AU - Kawahara, Shin

AU - Harita, Shingo

AU - Sato, Toshio

AU - Kobayashi, Makoto

AU - Eguchi, Kenji

AU - Hiraki, Shunkichi

AU - Hiraki, Yoshio

AU - Tanimoto, Mitsune

PY - 2002/5

Y1 - 2002/5

N2 - Eighteen elderly patients aged 76 years or older with small cell lung cancer were treated with carboplatin (AUC = 4 mg/ml.min, i.v. day 1) and etoposide (70 mg/m2 i.v. day 1-3) and 17 patients were evaluable. The median age of the study population was 77 years (range: 76-81). Eight patients had limited disease (LD) and nine did extensive disease (ED). The overall response rate was 88% for LD patients and 67% for ED patients. Median survival time was 219 days for LD patients and 158 days for ED patients. Grade 3 and 4 leukopenia, neutropenia, thrombocytopenia and anemia occurred in 41%, 76%, 24% and 6% of patients, respectively. There was one treatment-related death due to pneumonitis.

AB - Eighteen elderly patients aged 76 years or older with small cell lung cancer were treated with carboplatin (AUC = 4 mg/ml.min, i.v. day 1) and etoposide (70 mg/m2 i.v. day 1-3) and 17 patients were evaluable. The median age of the study population was 77 years (range: 76-81). Eight patients had limited disease (LD) and nine did extensive disease (ED). The overall response rate was 88% for LD patients and 67% for ED patients. Median survival time was 219 days for LD patients and 158 days for ED patients. Grade 3 and 4 leukopenia, neutropenia, thrombocytopenia and anemia occurred in 41%, 76%, 24% and 6% of patients, respectively. There was one treatment-related death due to pneumonitis.

UR - http://www.scopus.com/inward/record.url?scp=0036560609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036560609&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 751

EP - 756

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 5

ER -